ReviewClinical pharmacology and therapeutics2020
Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics.
Erratum issued 2 registry-linked trialsOpen access · hybridAbstract readReview
In one paragraph
Review in Clinical pharmacology and therapeutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 2 registered trials, which are not on this map. Cited by 85 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
85citing papers in PubMed, 2 pooled it
3.7field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized, Open Label Trial to Investigate the Efficacy and Safety of Nitazoxanide Plus Atazanavir/Ritonavir for the Treatment of COVID-19: a Pilot Study
Prognostic Modification in Patients With COVID-19 Under Early Intervention Treatment at U.M.F 13 and U.M.F 20
Who cites it
85 citing papers in PubMed, 2 syntheses or guidelines pooled it, 167 citations in OpenAlex.
- Systematic Review and Patient-Level Meta-Analysis of SARS-CoV-2 Viral Dynamics to Model Response to Antiviral Therapies.Clinical pharmacology and therapeutics · 2021Pooled it
- Meta-analysis on outcome-worsening comorbidities of COVID-19 and related potential drug-drug interactions.Pharmacological research · 2020Pooled it
- Population pharmacokinetic/pharmacodynamic modelling to evaluate favipiravir in combination with lopinavir-ritonavir in patients with COVID-19.British journal of clinical pharmacology · 2026Trial
- Optimal Dose and Safety of Intravenous Favipiravir in Hospitalized Patients With COVID-19: A Dose-Escalating, Randomized Controlled Phase Ib Study.Clinical pharmacology and therapeutics · 2026Trial
- Favipiravir, lopinavir-ritonavir, or combination therapy (FLARE): A randomised, double-blind, 2 × 2 factorial placebo-controlled trial of early antiviral therapy in COVID-19.PLoS medicine · 2022Trial
- Randomized clinical trial of nitazoxanide or sofosbuvir/daclatasvir for the prevention of SARS-CoV-2 infection.The Journal of antimicrobial chemotherapy · 2022Trial
- Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial.Intensive care medicine · 2021Trial
- Translational stewardship in pandemic therapeutics: ivermectin, evidentiary misalignment, and the propagation of constraints.Journal of translational medicine · 2026Article
- Bazedoxifene and Beyond: Identifying This SERM's Targets and Deciphering Its Molecular Mechanisms.Advances in pharmacological and pharmaceutical sciences · 2026Review
- A Pilot, Randomised, Placebo-Controlled, Double-Blind Trial of a Single Oral Dose of Ivermectin for Post-Exposure Prophylaxis of SARS-CoV-2.Pharmaceutics · 2025Article
- Translational Success and Pharmacoeconomic Lessons of Pandemic-Driven Drug Repurposing.Cureus · 2025Review
- Endolysosome-targeted nanoparticle delivery of antiviral therapy for coronavirus infections.Life science alliance · 2025Article
- Antimalarial compounds exhibit variant- and cell-type-specific activity against SARS-CoV-2 isolated in Panama.Frontiers in pharmacology · 2025Article
- Favipiravir pharmacokinetics in Thai adults with mild COVID-19: A sub-study of interpatient variability and ethnic differences in exposure.Pharmacology research & perspectives · 2024Article
- Evaluation of potency and metabolic stability of diphyllin-derived Vacuolar-ATPase inhibitors.European journal of medicinal chemistry · 2024Article
- Potential therapeutic biomolecules of hymenopteran venom against SARS-CoV-2 from Egyptian patients.Scientific reports · 2024Article
- Effect of drug therapies on self-reported chemosensory outcomes after COVID-19.World journal of otorhinolaryngology - head and neck surgery · 2024Article
- Article
- Article
- Cytokine Storm-Induced Thyroid Dysfunction in COVID-19: Insights into Pathogenesis and Therapeutic Approaches.Drug design, development and therapy · 2024Review
25 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
22 authors at 3 institutions in 1 country.
Usman ArshadDepartment of Molecular and Clinical Pharmacology, Materials Innovation Factory, University of Liverpool, Liverpool, UK.ORCID 0000-0003-1586-1885
Henry PertinezDepartment of Molecular and Clinical Pharmacology, Materials Innovation Factory, University of Liverpool, Liverpool, UK.
Helen BoxDepartment of Molecular and Clinical Pharmacology, Materials Innovation Factory, University of Liverpool, Liverpool, UK.
Lee TathamDepartment of Molecular and Clinical Pharmacology, Materials Innovation Factory, University of Liverpool, Liverpool, UK.
Rajith K R RajoliDepartment of Molecular and Clinical Pharmacology, Materials Innovation Factory, University of Liverpool, Liverpool, UK.
Paul CurleyDepartment of Molecular and Clinical Pharmacology, Materials Innovation Factory, University of Liverpool, Liverpool, UK.ORCID 0000-0003-4596-2708
Megan NearyDepartment of Molecular and Clinical Pharmacology, Materials Innovation Factory, University of Liverpool, Liverpool, UK.ORCID 0000-0002-4960-2139
Joanne SharpDepartment of Molecular and Clinical Pharmacology, Materials Innovation Factory, University of Liverpool, Liverpool, UK.
Neill J LiptrottDepartment of Molecular and Clinical Pharmacology, Materials Innovation Factory, University of Liverpool, Liverpool, UK.ORCID 0000-0002-5980-8966
Anthony ValentijnDepartment of Molecular and Clinical Pharmacology, Materials Innovation Factory, University of Liverpool, Liverpool, UK.
Christopher DavidDepartment of Molecular and Clinical Pharmacology, Materials Innovation Factory, University of Liverpool, Liverpool, UK.ORCID 0000-0001-8504-2354
Steve P RannardDepartment of Chemistry, University of Liverpool, Liverpool, UK.ORCID 0000-0002-6946-1097
Paul M O'NeillDepartment of Chemistry, University of Liverpool, Liverpool, UK.
Ghaith AljayyoussiDepartment of Tropical Disease Biology, Liverpool School of Tropical Medicine, Centre for Drugs and Diagnostics, Liverpool, UK.ORCID 0000-0002-5288-4501
Shaun H PenningtonDepartment of Tropical Disease Biology, Liverpool School of Tropical Medicine, Centre for Drugs and Diagnostics, Liverpool, UK.ORCID 0000-0002-7160-6275
Stephen A WardDepartment of Tropical Disease Biology, Liverpool School of Tropical Medicine, Centre for Drugs and Diagnostics, Liverpool, UK.ORCID 0000-0003-2331-3192
Andrew HillDepartment of Molecular and Clinical Pharmacology, Materials Innovation Factory, University of Liverpool, Liverpool, UK.
David J BackDepartment of Molecular and Clinical Pharmacology, Materials Innovation Factory, University of Liverpool, Liverpool, UK.
Saye H KhooDepartment of Molecular and Clinical Pharmacology, Materials Innovation Factory, University of Liverpool, Liverpool, UK.
Patrick G BrayPat Bray Electrical, Wigan, UK.
Giancarlo A BiaginiDepartment of Tropical Disease Biology, Liverpool School of Tropical Medicine, Centre for Drugs and Diagnostics, Liverpool, UK.ORCID 0000-0001-6356-6595
Andrew OwenDepartment of Molecular and Clinical Pharmacology, Materials Innovation Factory, University of Liverpool, Liverpool, UK.ORCID 0000-0002-9819-7651
University of Liverpool · GBLiverpool School of Tropical Medicine · GBWrightington, Wigan and Leigh NHS Foundation Trust · GB
Funding
The Long-Acting/Extended Release Antiretroviral Resource Program (LEAP)R24AI118397 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Charles W. Flexner · 2015 to 2026
$9.4MLong acting NRTI therapies for HIVR01AI134091 · NIAID · JOHNS HOPKINS UNIVERSITY · PI FREEL MEYERS, CAREN L., RANNARD, STEVE · 2017 to 2021
$3.1MMedical Research Council MC_PC_17167Medical Research Council MR/S00467X/1NIAID NIH HHS R01 AI134091NIAID NIH HHS R24 AI118397
Abstract
There is a rapidly expanding literature on the in vitro antiviral activity of drugs that may be repurposed for therapy or chemoprophylaxis against severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2). However, this has not been accompanied by a comprehensive evaluation of the target plasma and lung concentrations of these drugs following approved dosing in humans. Accordingly, concentration 90% (EC
Indexed as
Antiviral AgentsBetacoronavirusCoronavirus InfectionsCOVID-19Drug Delivery SystemsDrug RepositioningHumansPandemicsPneumonia, ViralSARS-CoV-2Antiviral Agents
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
NCT04459286ClinicalTrials.gov
NCT04673214ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.